{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T15:53:16Z","timestamp":1769356396939,"version":"3.49.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Dokuchaev Soil Science Institute"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,20]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This prospective single-arm trial with historic controls evaluated the efficacy and safety of treatment based on a combination of rituximab, intravenous cyclophosphamide and corticosteroids (RCP) administered at lower cumulative doses for the induction of early remission in primary membranous nephropathy (PMN).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We prospectively enrolled 30 high-risk PMN patients with persistent nephrotic syndrome (NS) and elevated antibodies to the phospholipase A2 receptor who underwent RCP therapy. We compared the effectiveness of RCP with that of historic controls who received rituximab-based therapy (RTX, n\u00a0=\u00a015) or cyclosporine\u00a0+\u00a0corticosteroids (CSA, n\u00a0=\u00a042). The primary outcomes were complete remission (CR) and overall remission (OR) by Month 12 and the time to remission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the RCP group, the OR and CR rates by 12\u00a0months (97% and 60%) were higher than those in the RTX group (60% and 7%, P\u00a0\u2264\u00a0.009) and the CSA group (50% and 24%, P\u00a0\u2264\u00a0.003). The median time to OR [2.8 (1.6\u20133.9) months] was shorter compared with RTX [7.1 (3.4\u201317.5) months, P\u00a0=\u00a0.008] and CSA [7.3 (6.0\u201313.6) months, P\u00a0&amp;lt;\u00a0.001]. In adjusted Cox regression, hazard ratios for OR and CR attainment for RCP versus other treatments were 5.2 (95% CI 2.8\u20139.6) and 4.8 (95% CI 2.2\u201310.3), respectively. Propensity score\u2013matched group analyses confirmed these results. One serious adverse event occurred in the RCP group in the follow-up of 56 patient-years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>RCP therapy is considered effective and safe for inducing early remission in high-risk PMN patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfae138","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T01:31:37Z","timestamp":1718674297000},"page":"60-70","source":"Crossref","is-referenced-by-count":5,"title":["A novel approach to induce early remission in high-risk primary membranous nephropathy"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8433-876X","authenticated-orcid":false,"given":"Zinaida","family":"Kochoyan","sequence":"first","affiliation":[{"name":"Research Institute of Nephrology, Pavlov University , Saint Petersburg ,","place":["Russian Federation"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7179-5520","authenticated-orcid":false,"given":"Vladimir A","family":"Dobronravov","sequence":"additional","affiliation":[{"name":"Research Institute of Nephrology, Pavlov University , Saint Petersburg ,","place":["Russian Federation"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"2025010614200143300_bib1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"2025010614200143300_bib2","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1681\/ASN.2020111583","article-title":"Primary nephrotic syndrome and risks of ESKD, cardiovascular events, and death: the Kaiser Permanente Nephrotic Syndrome Study","volume":"32","author":"Go","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2025010614200143300_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.24920\/11809","article-title":"A cohort study of incidence and risk factors for thromboembolic events in patients with idiopathic membranous nephropathy","volume":"33","author":"Zou","year":"2018","journal-title":"Chin Med Sci J"},{"key":"2025010614200143300_bib4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0270-9295(03)00050-0","article-title":"Nonimmunosuppressive therapy of membranous nephropathy","volume":"23","author":"Schieppati","year":"2003","journal-title":"Semin Nephrol"},{"key":"2025010614200143300_bib5","first-page":"50","article-title":"KDIGO 2021 Clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney Int"},{"key":"2025010614200143300_bib6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/ckj\/sfv075","article-title":"A European multicentre and open-label controlled randomized trial to evaluate the efficacy of sequential treatment with tacrolimus-rituximab versus steroids plus cyclophosphamide in patients with primary membranous nephropathy: the STARMEN study","volume":"8","author":"Rojas-Rivera","year":"2015","journal-title":"Clin Kidney J"},{"key":"2025010614200143300_bib7","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2025010614200143300_bib8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"2025010614200143300_bib9","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.3346\/jkms.2018.33.e74","article-title":"The effect of mycophenolate mofetil versus cyclosporine as combination therapy with low dose corticosteroids in high-risk patients with idiopathic membranous nephropathy: a multicenter randomized trial","volume":"33","author":"Choi","year":"2018","journal-title":"J Korean Med Sci"},{"key":"2025010614200143300_bib10","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2025010614200143300_bib11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/MAJ.0b013e3181ca3a7d","article-title":"Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial","volume":"339","author":"Chen","year":"2010","journal-title":"Am J Med Sci"},{"key":"2025010614200143300_bib12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000348475","article-title":"Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial","volume":"181","author":"Xu","year":"2013","journal-title":"Contrib Nephrol"},{"key":"2025010614200143300_bib13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40265-021-01656-1","article-title":"Recent clinical trials insights into the treatment of primary membranous nephropathy","volume":"82","author":"Rojas-Rivera","year":"2022","journal-title":"Drugs"},{"key":"2025010614200143300_bib14","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s40620-022-01268-2","article-title":"Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network metaanalysis","volume":"35","author":"Bose","year":"2022","journal-title":"J Nephrol"},{"key":"2025010614200143300_bib15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.nefroe.2019.05.003","article-title":"A comparison of cyclophosphamide versus tacrolimus in terms of treatment effect for idiopathic membranous nephropathy: a meta-analysis","volume":"39","author":"Li","year":"2019","journal-title":"Nefrologia (Engl Ed)"},{"key":"2025010614200143300_bib16","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.2147\/DDDT.S209211","article-title":"Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis","volume":"13","author":"Lin","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"2025010614200143300_bib17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/0886022X.2019.1605294","article-title":"Baseline proteinuria level is associated with prognosis in idiopathic membranous nephropathy","volume":"41","author":"Chen","year":"2019","journal-title":"Ren Fail"},{"key":"2025010614200143300_bib18","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.ekir.2021.04.002","article-title":"Anti-PLA2R1 antibodies as prognostic biomarker in membranous nephropathy","volume":"6","author":"van de Logt","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025010614200143300_bib19","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1007\/s11255-020-02588-7","article-title":"The association of anti-PLA2R with clinical manifestations and outcomes in idiopathic membranous nephropathy: a meta-analysis","volume":"52","author":"Rao","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"2025010614200143300_bib20","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.2215\/CJN.0000000000000237","article-title":"Anti-PLA2R antibody levels and clinical risk factors for treatment nonresponse in membranous nephropathy","volume":"18","author":"Barbour","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025010614200143300_bib21","article-title":"Rituximab, Cyclophospamide, and Corticosteroids in Primary Membranous Nephropathy","author":"CinicalTrials.gov"},{"key":"2025010614200143300_bib22","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1002\/sim.5705","article-title":"The performance of different propensity score methods for estimating marginal hazard ratios","volume":"32","author":"Austin","year":"2013","journal-title":"Stat Med"},{"key":"2025010614200143300_bib23","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2025010614200143300_bib24","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The robust inference for the cox proportional hazards model","volume":"84","author":"Lin","year":"1989","journal-title":"J Am Statist Assoc"},{"key":"2025010614200143300_bib25","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2022"},{"key":"2025010614200143300_bib26","doi-asserted-by":"publisher","first-page":"786334","DOI":"10.3389\/fphar.2021.786334","article-title":"Efficacy and safety of different immunosuppressive therapies in patients with membranous nephropathy and high PLA2R antibody titer","volume":"12","author":"Deng","year":"2021","journal-title":"Front. Pharmacol"},{"key":"2025010614200143300_bib27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1681\/ASN.2017070734","article-title":"Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy","volume":"29","author":"Seitz-Polski","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2025010614200143300_bib28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1681\/ASN.2019030273","article-title":"Clinical relevance of domain-specific phospholipase A2 receptor 1 antibody levels in patients with membranous nephropathy","volume":"31","author":"Reinhard","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2025010614200143300_bib29","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int"},{"key":"2025010614200143300_bib30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/4996239","article-title":"Treatment of idiopathic membranous nephropathy for moderate or severe proteinuria: a systematic review and network meta-analysis","volume":"2022","author":"Chen","year":"2022","journal-title":"Int J Clin Pract"},{"key":"2025010614200143300_bib31","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1007\/s11255-022-03169-6","article-title":"Efficacy and safety of tacrolimus combined with corticosteroids in patients with idiopathic membranous nephropathy: systematic review and meta-analysis of randomized controlled trials","volume":"54","author":"Tian","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"2025010614200143300_bib32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s40265-016-0683-z","article-title":"Efficacy and Safety of tacrolimus versus cyclophosphamide for primary membranous: a meta-analysis","volume":"77","author":"Zhu","year":"2017","journal-title":"Drugs"},{"key":"2025010614200143300_bib33","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"2025010614200143300_bib34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/nep.12569","article-title":"Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial","volume":"21","author":"Ramachandran","year":"2016","journal-title":"Nephrology"},{"key":"2025010614200143300_bib35","first-page":"CD004293","article-title":"Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome","volume":"10","author":"Chen","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025010614200143300_bib36","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.nephro.2021.10.002","article-title":"Evaluation of efficacy of rituximab for membranous nephropathy: a systematic review and meta-analysis of 11 studies","volume":"18","author":"Ou","year":"2022","journal-title":"Nephrol Ther"},{"key":"2025010614200143300_bib37","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: A 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2025010614200143300_bib38","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.3906\/sag-2104-177","article-title":"Rituximab for the treatment of idiopathic membranous nephropathy with nephrotic syndrome: a systematic review and meta-analysis","volume":"51","author":"You","year":"2021","journal-title":"Turk J Med Sci"},{"key":"2025010614200143300_bib39","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025010614200143300_bib40","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.34067\/KID.0001432021","article-title":"Rituximab is preferable to cyclophosphamide for treatment of membranous nephropathy: CON","volume":"2","author":"van de Logt","year":"2021","journal-title":"Kidney360"},{"key":"2025010614200143300_bib41","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fern\u00e1ndez-Ju\u00e1rez","year":"2021","journal-title":"Kidney Int"},{"key":"2025010614200143300_bib42","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet North Am Ed"},{"key":"2025010614200143300_bib43","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2025010614200143300_bib44","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.kint.2018.08.045","article-title":"Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody","volume":"95","author":"Dahan","year":"2019","journal-title":"Kidney Int"},{"key":"2025010614200143300_bib45","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.kint.2017.12.019","article-title":"Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab","volume":"93","author":"van de Logt","year":"2018","journal-title":"Kidney Int"},{"key":"2025010614200143300_bib46","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titre predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025010614200143300_bib47","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1053\/j.ajkd.2021.04.014","article-title":"Combination of rituximab, low-dose cyclophosphamide, and prednisone for primary membranous nephropathy: a case series with extended follow up","volume":"78","author":"Zonozi","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2025010614200143300_bib48","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ekir.2022.12.011","article-title":"Novel treatments paradigms: membranous nephropathy","volume":"8","author":"Rojas-Rivera","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025010614200143300_bib49","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ekir.2016.05.002","article-title":"Membranous nephropathy: pilot study of a novel regimen combining cyclosporine and rituximab","volume":"1","author":"Walman","year":"2016","journal-title":"Kidney Int Rep"},{"key":"2025010614200143300_bib50","doi-asserted-by":"publisher","first-page":"1110355","DOI":"10.3389\/fneph.2023.1110355","article-title":"Treatment of membranous nephropathy: perspectives on current and future therapies","volume":"3","author":"Shah","year":"2023","journal-title":"Front Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfae138\/58753853\/gfae138.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/1\/60\/58753853\/gfae138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/1\/60\/58753853\/gfae138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T14:20:13Z","timestamp":1736173213000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/1\/60\/7695324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,6,17]]},"published-print":{"date-parts":[[2024,12,20]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae138","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,6,17]]}}}